BLCO vs. STAA, RXST, EYE, WRBY, COO, OPCH, GKOS, HALO, BPMC, and CRSP
Should you be buying Bausch + Lomb stock or one of its competitors? The main competitors of Bausch + Lomb include STAAR Surgical (STAA), RxSight (RXST), National Vision (EYE), Warby Parker (WRBY), Cooper Companies (COO), Option Care Health (OPCH), Glaukos (GKOS), Halozyme Therapeutics (HALO), Blueprint Medicines (BPMC), and CRISPR Therapeutics (CRSP). These companies are all part of the "medical" sector.
Bausch + Lomb (NYSE:BLCO) and STAAR Surgical (NASDAQ:STAA) are both mid-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their profitability, media sentiment, valuation, risk, dividends, analyst recommendations, institutional ownership, earnings and community ranking.
11.1% of Bausch + Lomb shares are owned by institutional investors. Comparatively, 96.7% of STAAR Surgical shares are owned by institutional investors. 1.1% of STAAR Surgical shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.
Bausch + Lomb has a beta of 0.36, indicating that its share price is 64% less volatile than the S&P 500. Comparatively, STAAR Surgical has a beta of 0.86, indicating that its share price is 14% less volatile than the S&P 500.
In the previous week, Bausch + Lomb had 7 more articles in the media than STAAR Surgical. MarketBeat recorded 8 mentions for Bausch + Lomb and 1 mentions for STAAR Surgical. STAAR Surgical's average media sentiment score of 1.06 beat Bausch + Lomb's score of -0.33 indicating that STAAR Surgical is being referred to more favorably in the news media.
Bausch + Lomb presently has a consensus target price of $19.50, suggesting a potential upside of 31.22%. STAAR Surgical has a consensus target price of $46.38, suggesting a potential upside of 0.38%. Given Bausch + Lomb's stronger consensus rating and higher probable upside, equities analysts clearly believe Bausch + Lomb is more favorable than STAAR Surgical.
STAAR Surgical has lower revenue, but higher earnings than Bausch + Lomb. Bausch + Lomb is trading at a lower price-to-earnings ratio than STAAR Surgical, indicating that it is currently the more affordable of the two stocks.
STAAR Surgical has a net margin of 6.62% compared to Bausch + Lomb's net margin of -6.27%. STAAR Surgical's return on equity of 8.73% beat Bausch + Lomb's return on equity.
STAAR Surgical received 262 more outperform votes than Bausch + Lomb when rated by MarketBeat users. Likewise, 56.35% of users gave STAAR Surgical an outperform vote while only 37.93% of users gave Bausch + Lomb an outperform vote.
Summary
STAAR Surgical beats Bausch + Lomb on 13 of the 18 factors compared between the two stocks.
Get Bausch + Lomb News Delivered to You Automatically
Sign up to receive the latest news and ratings for BLCO and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding BLCO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Bausch + Lomb Competitors List
Related Companies and Tools
